Metraipolis › archive › dc_b8be3eaa536a

A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes — Europe PMC PMID:41303207

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41303207
DOI
10.3390/jcm14228170
License (as archived)
solo-consultazione
Archived
2026-11-08T11:16:50.073Z
SHA-256 of the archived text
012834bf06f92dae151f562b313c13e7e54aeb32fefb173efd6cfbbdf090236c
Stable URL of this page
https://metraipolis.com/documento/dc_b8be3eaa536a

How to cite

A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes — Europe PMC PMID:41303207 — Europe PMC (en), https://europepmc.org/article/MED/41303207 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_b8be3eaa536a (Metraipolis archive dc_b8be3eaa536a, sha256 012834bf06f92dae151f562b313c13e7e54aeb32fefb173efd6cfbbdf090236c)
BibTeX
@misc{dcb8be3eaa536a,
  title = {A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes — Europe PMC PMID:41303207},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41303207},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_b8be3eaa536a; sha256 012834bf06f92dae151f562b313c13e7e54aeb32fefb173efd6cfbbdf090236c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41303207. Agents can read the archived copy with the MCP tool read_document.